drugset / Trial / NCT07223047
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
Timeline
- Start
- 2025-11-25
- Primary completion
- 2028-10-13
- Completion
- 2028-10-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986523 | Unknown | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |